VolitionRx (NYSE:VNRX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note released on Tuesday morning,Benzinga reports. They currently have a $2.50 target price on the stock.

Several other equities research analysts have also issued reports on the company. Jones Trading raised VolitionRx to a “strong-buy” rating and set a $3.00 price target for the company in a research note on Tuesday, June 10th. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $3.50.

VolitionRx Stock Up 9.0%

Shares of VNRX stock opened at $0.68 on Tuesday. The business has a 50-day moving average price of $0.65 and a two-hundred day moving average price of $0.60. VolitionRx has a 12-month low of $0.40 and a 12-month high of $0.94. The firm has a market cap of $73.04 million, a P/E ratio of -1.89 and a beta of 1.27.

Insider Activity

In related news, Director Guy Archibald Innes acquired 78,125 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director owned 966,814 shares in the company, valued at approximately $618,760.96. This represents a 8.79% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Cameron John Reynolds acquired 78,125 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The stock was bought at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the acquisition, the chief executive officer owned 2,609,847 shares of the company’s stock, valued at approximately $1,670,302.08. This trade represents a 3.09% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 171,250 shares of company stock worth $109,900. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in VolitionRx during the 4th quarter valued at about $36,000. Northern Trust Corp increased its holdings in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Silverberg Bernstein Capital Management LLC increased its holdings in VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after purchasing an additional 60,209 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in VolitionRx during the 2nd quarter valued at about $52,000. Finally, Armistice Capital LLC increased its holdings in VolitionRx by 3.5% during the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock valued at $6,455,000 after purchasing an additional 286,644 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.